Authors find 19 percent increased risk for antidepressant Rx among previously naive adults<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, May 15, 2024 (HealthDay News) — Individuals taking glucagon-like peptide (GLP)-1 receptor agonists have a greater risk for subsequently being dispensed antidepressants, according to a study published online April 23 in\u00a0Diabetes, Obesity, and Metabolism<\/em>.<\/p>\n Osvaldo P. Almeida, Ph.D., from University of Notre Dame in Fremantle, Australia, and colleagues assessed whether dispensing of GLP-1 receptor agonists is associated with increased dispensing of antidepressants. The analysis included a 10 percent random sample of the Australian Pharmaceutical Benefits Scheme data (2012 to 2022).<\/p>\n The researchers found that 358,075 of 1.7 million individuals were dispensed antidepressants, and 8,495 of the 24,783 dispensed a GLP-1 receptor agonist were also dispensed an antidepressant in 2022 (odds ratio, 1.44). Among 24,103 individuals dispensed a GLP-1 receptor agonist between 2012 and 2021, 8,083 were dispensed antidepressants in 2022 (odds ratio, 1.52). Among 1.2 million individuals who had not been dispensed antidepressants in 2012, there was a heightened risk for being dispensed an antidepressant between 2013 and 2022 following the dispensing of a GLP-1 receptor agonist (hazard ratio, 1.19).<\/p>\n “Individuals exposed to GLP-1 receptor agonists are at greater risk of being dispensed antidepressants,” the authors write. “The possible impact of GLP-1 receptor agonists on the mood of consumers requires ongoing vigilance and further research.”<\/p>\n